stockportfolio.pro
Stocks / CYTK vs RGC
CYTK vs RGC
Cytokinetics, Incorporated and Regencell Bioscience Holdings Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Cytokinetics, Incorporated (CYTK) | Regencell Bioscience Holdings Limited (RGC) | |
|---|---|---|
| Market cap | $9.1B | $9.3B |
| Revenue (latest FY) | $88.04M | $0 |
| Net income (latest FY) | $-784.96M | $-4.30M |
| Revenue growth (5y CAGR) | 9.5% | — |
| Net margin | -891.6% | — |
| Return on equity | 119.0% | -52.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CYTK — free Open RGC — freeFrequently asked questions
Which is bigger, CYTK or RGC?
Regencell Bioscience Holdings Limited is larger by market capitalization — $9.3B versus $9.1B.
Which grows faster, CYTK or RGC?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.